64304500CRD2001: A Phase 2b Randomized Double-blind Placebo-controlled Parallel-group Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active Crohn?s Disease

Brief description of study

The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease


Clinical Study Identifier: s16-00963
ClinicalTrials.gov Identifier: NCT02877134
Principal Investigator: Seymour Katz
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.